Meeder Advisory Services Inc. Makes New $230,000 Investment in Medpace Holdings, Inc. (NASDAQ:MEDP)

Meeder Advisory Services Inc. bought a new position in Medpace Holdings, Inc. (NASDAQ:MEDP) in the first quarter, according to its most recent disclosure with the SEC. The firm bought 568 shares of the company’s stock, valued at approximately $230,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Vanguard Group Inc. increased its stake in shares of Medpace by 5.9% in the 4th quarter. Vanguard Group Inc. now owns 2,556,443 shares of the company’s stock worth $783,626,000 after acquiring an additional 142,591 shares during the last quarter. Riverbridge Partners LLC grew its holdings in shares of Medpace by 7.1% during the 4th quarter. Riverbridge Partners LLC now owns 652,384 shares of the company’s stock worth $199,975,000 after purchasing an additional 43,197 shares during the period. TD Asset Management Inc grew its holdings in shares of Medpace by 195.2% during the 4th quarter. TD Asset Management Inc now owns 467,041 shares of the company’s stock worth $143,162,000 after purchasing an additional 308,816 shares during the period. Wellington Management Group LLP grew its holdings in shares of Medpace by 312.6% during the 3rd quarter. Wellington Management Group LLP now owns 421,313 shares of the company’s stock worth $102,013,000 after purchasing an additional 319,210 shares during the period. Finally, Epoch Investment Partners Inc. grew its holdings in shares of Medpace by 82.3% during the 4th quarter. Epoch Investment Partners Inc. now owns 352,463 shares of the company’s stock worth $108,040,000 after purchasing an additional 159,144 shares during the period. 77.98% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Medpace

In other Medpace news, CEO August J. Troendle sold 15,102 shares of Medpace stock in a transaction that occurred on Monday, April 29th. The stock was sold at an average price of $400.69, for a total transaction of $6,051,220.38. Following the transaction, the chief executive officer now owns 791,541 shares of the company’s stock, valued at $317,162,563.29. The transaction was disclosed in a filing with the SEC, which is available at this link. In other Medpace news, CEO August J. Troendle sold 15,102 shares of Medpace stock in a transaction that occurred on Monday, April 29th. The stock was sold at an average price of $400.69, for a total transaction of $6,051,220.38. Following the transaction, the chief executive officer now owns 791,541 shares of the company’s stock, valued at $317,162,563.29. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO August J. Troendle sold 3,987 shares of Medpace stock in a transaction that occurred on Friday, May 24th. The stock was sold at an average price of $395.22, for a total value of $1,575,742.14. Following the transaction, the chief executive officer now directly owns 660,351 shares in the company, valued at approximately $260,983,922.22. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 29,621 shares of company stock valued at $11,816,852. Corporate insiders own 20.30% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on MEDP shares. Guggenheim increased their price target on Medpace from $453.00 to $464.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. TD Cowen began coverage on Medpace in a report on Wednesday, May 29th. They set a “buy” rating and a $452.00 target price for the company. Deutsche Bank Aktiengesellschaft began coverage on Medpace in a report on Monday, March 18th. They set a “hold” rating and a $395.00 target price for the company. StockNews.com upgraded Medpace from a “hold” rating to a “buy” rating in a report on Thursday, July 11th. Finally, Robert W. Baird increased their price target on Medpace from $456.00 to $469.00 and gave the company an “outperform” rating in a research report on Monday, July 8th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $445.29.

Medpace Stock Performance

MEDP stock traded up $8.81 during mid-day trading on Tuesday, reaching $453.29. The company had a trading volume of 31,250 shares, compared to its average volume of 227,075. Medpace Holdings, Inc. has a fifty-two week low of $227.21 and a fifty-two week high of $455.06. The company has a market capitalization of $14.04 billion, a price-to-earnings ratio of 45.31, a price-to-earnings-growth ratio of 2.19 and a beta of 1.36. The firm has a fifty day simple moving average of $401.95 and a 200 day simple moving average of $376.50.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, April 22nd. The company reported $3.20 earnings per share for the quarter, topping the consensus estimate of $2.45 by $0.75. Medpace had a return on equity of 59.74% and a net margin of 15.92%. The business had revenue of $511.00 million for the quarter, compared to analyst estimates of $512.39 million. During the same quarter last year, the company earned $2.27 EPS. The business’s quarterly revenue was up 17.7% on a year-over-year basis. As a group, analysts predict that Medpace Holdings, Inc. will post 11.29 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.